Annual report
7129.TEDINET S100YK3E
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 153
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥24.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥23.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥22.7bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥22.2bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥19.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥824m | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥641m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥828m | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥645m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥374m | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥169m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥190m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥437m | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥486m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥201m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥300m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥6m | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥210m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥292m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥201m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥300m | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥15.6bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥13.3bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥13.8bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.1bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥14.2bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.7bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥9.5bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.9bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.8bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥3.3bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥3.2bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥4.5bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥4.5bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.8bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.2bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.1bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥906m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.6bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.0bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥919m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥364m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥456m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥336m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥557m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥2.4bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥853m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥610m | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥369m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥2.0bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥71.83 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥113.95 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2.21 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥84.22 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥117.49 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥71.7 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥113.05 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥2.2 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.84 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥116.61 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,396.81 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,357.53 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,307.63 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,341.2 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,287.13 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 25.1% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.6% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.9% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.6% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.5% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 5.2% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 0.2% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.4% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,838 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 1,847 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,741 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 1,782 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 1,752 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥360m | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥321m | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥322m | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥278m | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥116m | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥146m | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥114m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥146m | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥114m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥124m | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥90m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥52m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥146m | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥114m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥108m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥84m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥94m | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥60m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥62m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥3.6bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥3.5bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥3.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.2bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.1bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥155m | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥128m | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥3.4bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥3.1bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥3.1bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥55m | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥208m | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥38.75 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.98 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥37.73 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.16 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥24.86 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥38.68 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.73 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥37.51 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.06 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥24.68 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥30 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,217.07 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,210.46 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,230.31 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,226.96 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,232.94 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 95.7% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.6% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 95.6% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 97.7% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 3.2% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.6% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.1% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 2,802,300 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,795,300 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,527,300 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,488,700 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 2,488,300 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 92
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2025-04-01 → 2026-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2025-04-01 → 2026-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2026-03-31 | 21 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-04-01 → 2026-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-04-01 → 2026-03-31 | ¥1.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥64m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2026-03-31 | ¥141m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2026-03-31 | ¥37m |
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥34m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥64m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥64m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥5.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥1.0bn |
| Childcaresupport Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥219m |
| Childcaresupport Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥394m |
| Childcaresupport Businessreportable segment | employees | at 2026-03-31 | 1292 pure |
| Childcaresupport Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥10.3bn |
| Childcaresupport Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥10.3bn |
| Childcaresupport Businessreportable segment | segment assets | at 2026-03-31 | ¥6.2bn |
| Childcaresupport Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.3bn |
| Medicine Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥192m |
| Medicine Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥111m |
| Medicine Businessreportable segment | employees | at 2026-03-31 | 183 pure |
| Medicine Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥9.9bn |
| Medicine Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥9.9bn |
| Medicine Businessreportable segment | segment assets | at 2026-03-31 | ¥2.8bn |
| Medicine Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥502m |
| Nursing Care Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥43m |
| Nursing Care Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥5m |
| Nursing Care Businessreportable segment | employees | at 2026-03-31 | 300 pure |
| Nursing Care Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥3.5bn |
| Nursing Care Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥3.5bn |
| Nursing Care Businessreportable segment | segment assets | at 2026-03-31 | ¥903m |
| Nursing Care Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥56m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥454m |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥510m |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥23.8bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥23.8bn |
| —segment total | segment assets | at 2026-03-31 | ¥9.9bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2025-04-01 → 2026-03-31 | ¥459m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2025-04-01 → 2026-03-31 | ¥514m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2026-03-31 | ¥24.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2026-03-31 | ¥24.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥64m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2026-03-31 | ¥10.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2026-03-31 | ¥1.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2024-04-01 → 2025-03-31 | ¥2m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥4m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2025-03-31 | ¥1.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥964m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥54m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2025-03-31 | ¥131m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥16m |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥17m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥18m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥54m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥54m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.6bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥973m |
| Childcaresupport Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥362m |
| Childcaresupport Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥411m |
| Childcaresupport Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥9.7bn |
| Childcaresupport Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥9.7bn |
| Childcaresupport Businessreportable segment | segment assets | at 2025-03-31 | ¥6.5bn |
| Childcaresupport Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Medicine Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥151m |
| Medicine Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥125m |
| Medicine Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Medicine Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥9.6bn |
| Medicine Businessreportable segment | segment assets | at 2025-03-31 | ¥3.1bn |
| Medicine Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥519m |
| Nursing Care Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥16m |
| Nursing Care Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥6m |
| Nursing Care Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Nursing Care Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥3.5bn |
| Nursing Care Businessreportable segment | segment assets | at 2025-03-31 | ¥917m |
| Nursing Care Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥9m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥529m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥542m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥22.9bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥22.9bn |
| —segment total | segment assets | at 2025-03-31 | ¥10.5bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥531m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥546m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥23.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥23.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥54m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥10.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥1.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,346
| Item | Context | Value | Unit |
|---|---|---|---|
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.6179 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 836100 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.2983 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 547000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.1952 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 100000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0356 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 100000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0356 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 60000 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0214 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 59100 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0210 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 40000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0142 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 40000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0142 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 30000 | |
| Shareholding ratio | CurrentYearInstant_No9MajorShareholdersMember | 0.0107 | |
| Number of shares held | CurrentYearInstant_No10MajorShareholdersMember | 21000 | |
| Shareholding ratio | CurrentYearInstant_No10MajorShareholdersMember | 0.0074 | |
| Number of shares held | CurrentYearInstant | 1833200 | |
| Shareholding ratio | CurrentYearInstant | 0.6542 | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 100 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 2800900 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 28009 | |
| Number of shares issued shares voting rights | CurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember | 1300 | |
| Number of shares issued shares voting rights | CurrentYearInstant | 2802300 | |
| Number of voting rights issued shares voting rights | CurrentYearInstant | 28009 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant_Row1Member | 100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant_Row1Member | 100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant_Row1Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentYearInstant | 100 | |
| Number of shares held in others names treasury shares etc | CurrentYearInstant | － | |
| Total number of shares held treasury shares etc | CurrentYearInstant | 100 | |
| Shareholding ratio treasury shares etc | CurrentYearInstant | 0.0000 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row1Member | 36350000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row1Member | 13.0 | |
| Total amount of dividends dividends of surplus | FilingDateInstant_Row2Member | 47637000 | JPY |
| Dividend per share dividends of surplus | FilingDateInstant_Row2Member | 17.0 | |
| Number of male directors and other officers | FilingDateInstant | 5 | |
| Number of female directors and other officers | FilingDateInstant | 2 | |
| Ratio of female directors and other officers | FilingDateInstant | 0.286 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000AokiFumieMember | 60000 | |
| Number of shares held ordinary shares information about directors and corporate auditors | FilingDateInstant_jpcrp030000-asr_E36714-000TakahashiMasahikoMember | 1000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |